Companies / REGN vs VTRS
REGN vs VTRS: Regeneron Pharmaceuticals and Viatris
Regeneron Pharmaceuticals (REGN) reported $14.3B in revenue against a 31.4% net margin, while Viatris (VTRS) reported $14.3B at a -24.6% net margin, most recently.
| Metric | REGN | VTRS |
|---|---|---|
| Revenue | $14.3B | $14.3B |
| Net Income | $4.5B | $-3.5B |
| Gross Margin | — | 35.1% |
| Operating Margin | 24.9% | -18.6% |
| EPS (Diluted) | $41.48 | $-3.00 |
| Free Cash Flow | $4.1B | $1.9B |
| Total Debt | $2.7B | $14.4B |
| P/E Ratio | 18.6× | n/m |
| P/B Ratio | n/m | n/m |
| Stock Price | $910.75 | $19.00 |
Free: last 5 years
| Fiscal year | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| REGN Revenue | ••••• | ••••• | ••••• | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| VTRS Revenue | ••••• | ••••• | ••••• | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |